2024 ICD-10-CM Diagnosis Code T80.89XS

Other complications following infusion, transfusion and therapeutic injection, sequela

ICD-10-CM Code:
T80.89XS
ICD-10 Code for:
Oth comp fol infusion, tranfs and theraputc inject, sequela
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Complications of surgical and medical care, not elsewhere classified
      (T80-T88)
      • Complications following infusion, transfusion and therapeutic injection
        (T80)

T80.89XS is a billable diagnosis code used to specify a medical diagnosis of other complications following infusion, transfusion and therapeutic injection, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

T80.89XS is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like other complications following infusion transfusion and therapeutic injection. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Abdominal hernia as complication of peritoneal dialysis
  • Acute disorder of hemodialysis
  • Acute disorder of hemodialysis
  • Acute megaloblastic anemia
  • Acute megaloblastic anemia
  • Acute megaloblastic anemia due to dialysis
  • Acute megaloblastic anemia secondary to total parenteral nutrition
  • Adverse reaction following injection of substance
  • Adynamic bone disease
  • Air in infusion or transfusion due to mechanical failure of apparatus
  • Allergic transfusion reaction
  • Alloimmune platelet transfusion refractoriness
  • Alloimmune thrombocytopenia
  • Blister at injection site
  • Bloodstained peritoneal dialysis effluent
  • Chronic kidney disease mineral and bone disorder
  • Complication of hemodialysis
  • Complication of hemodialysis
  • Complication of hemodialysis
  • Complication of hemodialysis
  • Complication of hemodialysis
  • Dialysis dementia
  • Dialysis disequilibrium syndrome
  • Dialysis fluid adverse reaction
  • Dialysis-associated ascites
  • Dialysis-associated hypoxia
  • Encapsulating peritoneal sclerosis associated with peritoneal dialysis
  • Erythema at injection site
  • Erythrocytosis due to autotransfusion
  • Extravasation due to and following blood transfusion
  • First use syndrome of dialysis
  • Hematoma of dialysis access site
  • Hemodialysis fluid adverse reaction
  • Hemodialysis-associated pruritus
  • Hemodialysis-associated pseudoporphyria
  • Hemofiltration solution adverse reaction
  • Hemolytic transfusion reaction
  • Hemoperitoneum as complication of peritoneal dialysis
  • Hemorrhage into peritoneal cavity
  • Hemosiderosis
  • Hydrothorax
  • Hydrothorax as complication of peritoneal dialysis
  • Hypercalcemia associated with chronic dialysis
  • Hyperchloremic acidosis associated with dialysis
  • Iatrogenic neonatal hyperglycemia
  • Inadequate hemodialysis
  • Inadequate peritoneal dialysis
  • Infusion site swelling
  • Injected limb mobility decreased
  • Injection neuropathy
  • Injection site anesthesia
  • Injection site atrophy
  • Injection site bruising
  • Injection site burning
  • Injection site cellulitis
  • Injection site cyst
  • Injection site dermatitis
  • Injection site edema
  • Injection site edema
  • Injection site eruption
  • Injection site eruption
  • Injection site fibrosis
  • Injection site hemorrhage
  • Injection site hypersensitivity
  • Injection site indentation
  • Injection site induration
  • Injection site inflammation
  • Injection site inflammation
  • Injection site inflammation
  • Injection site irritation
  • Injection site itching
  • Injection site malabsorption
  • Injection site mass
  • Injection site mass
  • Injection site necrosis
  • Injection site nerve damage
  • Injection site pain
  • Injection site paresthesia
  • Injection site pigmentation change
  • Injection site pruritus
  • Injection site thrombosis
  • Injection site urticaria
  • Injury due to and following infusion
  • Injury due to and following therapeutic injection
  • Injury due to and following transfusion
  • Intestinal obstruction due to a procedure
  • Lipoatrophy due to injected drug
  • Lipogranuloma
  • Localized lipoatrophy
  • Long-term disorder of dialysis
  • Long-term disorder of dialysis
  • Long-term disorder of dialysis
  • Loss of solute clearance
  • Matrix stone formation during renal dialysis
  • Mechanical failure of instrument or apparatus during infusion or transfusion
  • Mechanical failure of instrument or apparatus during kidney dialysis
  • Megaloblastic anemia due to hemodialysis
  • Megaloblastic anemia due to hyperalimentation
  • Metabolic acidosis, NAG, acidifying salts
  • Myelopathy post intrathecal injection of chemotherapeutic agent
  • Neonatal hyperbilirubinemia following total parenteral nutrition
  • Neonatal hyperglycemia
  • Neonatal hyperglycemia due to iatrogenic intravenous therapy
  • Neonatal polycythemia
  • Non-allergic hypersensitivity reaction caused by dialysis membrane
  • Non-allergic hypersensitivity reaction during dialysis
  • Nontraumatic hemoperitoneum
  • Osteonecrosis due to and following renal dialysis
  • Pain during inflow of dialysate
  • Pain during outflow of dialysate
  • Penile sclerosing lipogranuloma
  • Penile sclerosing lipogranuloma due to injected substance
  • Peritoneal dialysis solution adverse reaction
  • Peritoneal dialysis-associated peritonitis
  • Polycythemia neonatorum following blood transfusion
  • Polyserositis
  • Polyserositis syndrome of dialysis
  • Post-dialysis dementia
  • Pseudoporphyria
  • Pulmonary transfusion reaction
  • Sclerosing lipogranuloma
  • Sclerosing peritonitis
  • Sclerosing peritonitis as complication of peritoneal dialysis
  • Sequelae of hyperalimentation
  • Skin lesion associated with hemodialysis
  • Skin lesion associated with hemodialysis
  • Swelling at injection site
  • Thrombocytopenia due to extracorporeal circulation of blood
  • Thromboembolism following infusion, perfusion AND/OR transfusion
  • Transfusion hemosiderosis
  • Transfusion reaction due to products of cell metabolism
  • Transfusion reaction due to toxic effect of anticoagulant
  • Transfusion reaction due to toxic substance in blood
  • Ultrafiltration failure
  • Underdialysis
  • Urticarial transfusion reaction

Clinical Classification

Clinical Information

  • Hemosiderosis

    conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the mononuclear phagocyte system, without demonstrable tissue damage. the name refers to the presence of stainable iron in the tissue in the form of hemosiderin.
  • Hydrothorax

    a collection of watery fluid in the pleural cavity. (dorland, 27th ed)
  • Mononuclear Phagocyte System

    mononuclear cells with pronounced phagocytic ability that are distributed extensively in lymphoid and other organs. it includes macrophages and their precursors; phagocytes; kupffer cells; histiocytes; dendritic cells; langerhans cells; and microglia. the term mononuclear phagocyte system has replaced the former reticuloendothelial system, which also included less active phagocytic cells such as fibroblasts and endothelial cells. (from illustrated dictionary of immunology, 2d ed.)
  • Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis

    a rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. it occurs mostly in premenopausal women. the ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.
  • Sclerosing Peritonitis

    a rare peritoneal cavity disorder that is characterized by the development of dense fibrous tissue in the peritoneum and the creation of severe adhesions in the abdomen that result in partial or complete small bowel obstruction. it may be idiopathic or develop in patients who receive peritoneal dialysis treatment. patients present with abdominal distention and pain.
  • Neonatal Hyperglycemia

    blood glucose concentration above the upper limit of established reference ranges in a newborn.
  • Erdheim-Chester Disease|ECD|Lipogranulomatosis|Polyostotic Sclerosing Histiocytosis

    a very rare, multisystem non-langerhans cell histiocytosis that predominantly affects adults. it is characterized by the proliferation in the tissues of lipid-laden macrophages and the presence of multinucleated giant cells. it results in sclerosis of the long bones and failure of the affected organs. patients may present with bone pain, exophthalmos, ataxia, liver failure, kidney failure, and hypopituitarism.
  • Farber Lipogranulomatosis

    a very rare autosomal recessive metabolic disorder affecting lipid metabolism. it is caused by mutations in the asah1 gene and is characterized by fatty accumulation in the body tissues. patients develop lipogranulomas in the skin and internal organs, edema and pain in the joints and a hoarse voice. it may be associated with intellectual disability.
  • Large Lipogranuloma Assessment|LPGNLMLG|Large Lipogranuloma|Large Lipogranuloma

    an evaluation of the presence or degree of large lipogranuloma in a sample.
  • Lipogranuloma

    an inflammatory lesion comprised of lipoid material.
  • Hydrothorax

    the accumulation of serous fluid within the pleural cavity.
  • Pseudoporphyria

    a drug-induced photodermatosis characterized by skin fragility, erythema, and the appearance of tense bullae, erosions and scarring in the absence of abnormalities in porphyrin metabolism.

Coding Guidelines

The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Present on Admission (POA)

T80.89XS is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T80.89XS to ICD-9-CM

  • ICD-9-CM Code: 909.3 - Late eff surg/med compl
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.